Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.

The study will investigate immune cell subsets, and how the cells are modified by this therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo, and 12 mo.

Immune subsets will be analyzed by flow cytometry. Data are analyzed with ANOVA with repeated measures.

Inclusion Criteria:

• All patients who are eligible for Ocrelizumab therapy based on FDA criteria

Exclusion Criteria:

• All patients who are ineligible for Ocrelizumab therapy based on FDA criteria.
• Prior treatment with Alemtuzumab or stem cell therapy, or immune abnormalities that would interfere with planned tests.
• Hepatitis B and HIV infections.
• Pregnant or lactating women.
• Hypersensitivity to trial medications.